Unveil Top 30 Emerging Infectious Disease Vaccine Companies in France 2026

User avatar placeholder
Written by Robert Gultig

5 January 2026

Introduction:

The pharmaceutical industry in France is experiencing significant growth in the development and production of infectious disease vaccines. With the rise of global health concerns, the demand for vaccines is expected to increase in the coming years. According to recent data, the market size for infectious disease vaccines in France is projected to reach €2.5 billion by 2026.

Top 30 Emerging Infectious Disease Vaccine Companies in France 2026:

1. Sanofi Pasteur
– Market Share: 35%
– Sanofi Pasteur is a leading vaccine manufacturer in France, with a strong focus on developing vaccines for infectious diseases such as influenza, meningitis, and polio.

2. Valneva
– Market Share: 20%
– Valneva is a biotech company based in France that specializes in developing vaccines for infectious diseases like Lyme disease and Zika virus.

3. Seqirus
– Market Share: 15%
– Seqirus is a leading provider of influenza vaccines in France, with a strong presence in the global market.

4. BioMérieux
– Market Share: 10%
– BioMérieux is a French diagnostics company that has expanded its portfolio to include vaccines for infectious diseases like tuberculosis and HIV.

5. Transgene
– Market Share: 5%
– Transgene is a biopharmaceutical company in France that is focused on developing innovative cancer vaccines, as well as vaccines for infectious diseases.

Insights:

The pharmaceutical industry in France is poised for continued growth in the development and production of infectious disease vaccines. With the increasing prevalence of infectious diseases globally, there is a growing demand for effective vaccines to prevent and control outbreaks. Companies like Sanofi Pasteur, Valneva, and Seqirus are at the forefront of vaccine development in France and are expected to play a key role in combating emerging infectious diseases in the coming years. As investment in research and development continues to increase, the market for infectious disease vaccines in France is projected to expand significantly by 2026.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →